Review Article
How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer
Table 1
Molecules used in preclinical and clinical trials as RET tyrosine kinase inhibitors.
| Compound | Trade name | Structure | Targets | Clinical trials | Refs |
| PP1 | Zaleplon | Pyrazolopyrimidine | RET |
— |
[50] | PP2 |
| ZD6474 | Vandetanib | Anilinoquinazoline | RET; VEGFR; EGFR | Phase II | [51] |
| RPI-1 | — | Indolinone | RET; MET | — | [52] |
| SU5416 | Sunitinib | Butanedioic acid | VEGFR-2; PDGFR; c-KIT; RET; CSF-1R | Phase II | [53, 54] | SU11248 |
| ZD1839 | Gefitinib | Anilinoquinazoline | EGFR | Phase II | [55, 56] |
| BAY43-9006 | Sorafenib | Bis-aryl urea | RAF-1; BRAF; VEGFR-2/-3; PDGFR-B; Flt-3; c-KIT; RET | Phase II | [57, 58] |
| AMG706 | Motesanib diphosphate | Diphosphate salt | VEGFR; PDGFR; KIT; RET | Phase II | [59, 60] |
| AG-013736 | Axitinib | Benzamide | RET; VEGFR; PDGFR; c-KIT | Phase II | [61] |
| XL184/XL880 | | | VEGFR2; RET and MET | Phase III | [***] |
|
|
[***] Eder et al. [62]. LoRusso et al. [63]. Ross et al. [64]. Salgia et al. [65].
|